Similar Papers

Paper Title
Journal
Date
Author
Abstract 4271: Epidermal growth factor receptor variant III (EGFRvIII) expression initiates slower proliferation and signals through AKT and STAT3 in immortalized keratinocytes.
Hiroyuki Ozawa ... Harry Quon
Cancer Research | VOL. 73
Hiroyuki Ozawa, et. al.Hiroyuki Ozawa ... Harry Quon
15 Apr 2013
Abstract 4322: Efficacy of Sym004, a novel anti-EGFR antibody mixture, against EGFRvIII positive glioblastoma xenografts.
Stephen T Keir ... Ivan D Horak
Cancer Research | VOL. 73
Stephen T Keir, et. al.Stephen T Keir ... Ivan D Horak
15 Apr 2013
Data from Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in <i>EGFR</i>-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Bettina Hentschel ... Michael Weller
-
Bettina Hentschel, et. al.Bettina Hentschel ... Michael Weller
31 Mar 2023
Abstract 4587: Identification of a monoclonal antibody to treat HCC xenografts with EGFRvIII expression
Zonghai Li ... Bizhi Shi
Cancer Research | VOL. 71
Zonghai Li, et. al.Zonghai Li ... Bizhi Shi
15 Apr 2011
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
Daniel J Landsburg ... Cameron J Turtle
Journal for ImmunoTherapy of Cancer | VOL. 13
Daniel J Landsburg, et. al.Daniel J Landsburg ... Cameron J Turtle
09 Feb 2025
Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma
Ramya Ramaswami ... Chia-Ching Jackie Wang
Journal for ImmunoTherapy of Cancer | VOL. 13
Ramya Ramaswami, et. al.Ramya Ramaswami ... Chia-Ching Jackie Wang
06 Feb 2025
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
Troels Holz Borch ... Inge Marie Svane
Journal for ImmunoTherapy of Cancer | VOL. 13
Troels Holz Borch, et. al.Troels Holz Borch ... Inge Marie Svane
06 Feb 2025
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study
Michiel M Smeenk ... Willemijn S M E Theelen
Journal for ImmunoTherapy of Cancer | VOL. 13
Michiel M Smeenk, et. al.Michiel M Smeenk ... Willemijn S M E Theelen
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.